Small Cell Lung Cancer (SCLC)

The study evaluated lurbinectedin (Zepzelca) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine for adult patients with small cell lung cancer whose disease progressed following 1 prior platinum-containing line of therapy.

The agency granted fast track designation to irinotecan liposome injection for patients with small cell lung cancer who progressed following a first-line platinum-based regimen.

This study aimed to evaluate the prognostic impact of extrapulmonary cancers in patients with IPF, as most studies have previously focused on the effect of lung cancer on this patient population.

This study found that Black patients with extensive-stage small cell lung cancer were less likely to receive chemotherapy, as were elderly, uninsured, and those with non-private insurance.

Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.

The FDA granted priority review to the new drug application for trilaciclib for patients with small cell lung cancer being treated with chemotherapy.

The FDA approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer under accelerated approval based on overall response rate and duration of response in a phase 2 study.

A study, published in Nature Cancer, demonstrates the quick and evolving revolutions of resistance mechanisms in small cell lung cancer.